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Abstract 
A significant proportion of pharmaceuticals are fluorinated and selecting the site of fluorine 
incorporation can be an important beneficial part a drug development process.  Here we 
describe initial experiments aimed at the development of a general method of selecting 
optimum sites on pro-drug molecules for fluorination, so that metabolic stability may be 
improved.  Several model biphenyl derivatives were transformed by the fungus 
Cunninghamella elegans and the bacterium Streptomyces griseus, both of which contain 
cytochromes P450 that mimic oxidation processes in vivo, so that the site of oxidation could 
be determined.  Subsequently, fluorinated biphenyl derivatives were synthesised using 
appropriate Suzuki-Miyaura coupling reactions, positioning the fluorine atom at the pre-
determined site of microbial oxidation; the fluorinated biphenyl derivatives were incubated 
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with the microorganisms and the degree of oxidation assessed.  Biphenyl-4-carboxylic acid 
was transformed completely to 4’-hydroxybiphenyl-4-carboxylic acid by C. elegans but, in 
contrast, the 4’fluoro- analogue remained untransformed exemplifying the microbial 
oxidation – chemical fluorination concept.  2’-Fluoro- and 3’-fluoro-biphenyl-4-carboxylic 
acid were also transformed, but more slowly than the non-fluorinated biphenyl carboxylic 
acid derivative. Thus, it is possible to design compounds in an iterative fashion with a longer 
metabolic half-life by identifying the sites that are most easily oxidised by in vitro methods 
and subsequent fluorination without recourse to extensive animal studies.  
 
Introduction 
 
A convenient, rapid in vitro chemical-microbial method for establishing the structures of 
oxidative metabolites of drug-like systems and subsequent improvement of substrate 
oxidative stability by site selective fluorination at pre-identified, oxidatively sensitive 
positions is reported here. This strategy be of potential benefit to the drug development 
process. 
Xenobiotics such as drugs and toxins are commonly metabolised in the liver prior to 
excretion, and the main class of enzyme involved is the cytochromes P450 (CYP).  In 
humans there are 57 CYP isoforms responsible for oxidative or phase I metabolism of drugs1, 
and one of the key factors in drug design is modulating the rate of CYP-mediated 
transformation so that optimum efficacy can be achieved. In addition, as part of a drug 
development programme, the toxicity of metabolites must be assessed to complete regulatory 
approval2. Consequently, the identification, synthesis and isolation of drug metabolites are 
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key stages in medicinal chemistry campaigns and, in general, in vivo studies are used to 
assess metabolite identity with obvious resource implications.  
A simple in vitro method that successfully and accurately mimics mammalian 
metabolic processes would offer an attractive alternative to conventional resource-intensive 
bio- and medicinal chemistry approaches. Indeed, many chemical methods, such as the use of 
iron porphyrin systems, have been assessed as potential biomimetic cytochrome P450 mimics 
in vitro with varying degrees of success3. In complementary approaches, some 
microorganisms can transform drugs to mammalian metabolites, since they have CYP 
enzymes.  In particular, the zygomycete fungus Cunninghamella elegans, which has been 
widely studied as a model of mammalian metabolism of xenobiotic compounds 4, offers a 
non-chemical CYP biomimic. 
Over 30% of currently available and commercially valuable pharmaceuticals owe 
their biological activity to the presence of fluorine atoms within their structures providing an 
indication of the importance of fluorine incorporation for modifying drug stability, 
lipophilicity and effective pH range5 6-8. Indeed, a common strategy for increasing the half-
life of a drug in vivo is to introduce a fluorine atom at the metabolically labile sites 9.  An 
example of how dramatic this approach can be is observed in the development of the 
cholesterol uptake inhibitor drug Ezetimibe (SCH 58325), where optimization of the lead 
compound (SCH4861) included fluorination of the phenyl ring, preventing oxidation to the 
corresponding phenol derivative, and substitution of a methoxy group with fluorine 
preventing demethylation (Fig 1).  These changes and other structural modifications reduced 
metabolic degradation to such levels whereby the required dose for activity could be 
decreased by 55 times, while increasing activity 400-fold 10, 11. Therefore, in the sphere of 
fluorinated drug development, it would be very useful to easily determine the site of CYP-
catalysed oxidation in a drug candidate in vitro, so that the incorporation of a fluorine atom is 
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then made at the optimal position for increasing oxidative stability as a contributing approach 
to improving drug efficacy. 
 
 
Figure 1.  Structures of lead compound SCH48461 and its fluorinated analogue, the 
cholesterol inhibitor Ezetimib. 
 
A common motif in several drug classes is the biphenyl system12, and various valuable 
pharmaceuticals bearing this structural unit are given in Fig. 2. Previously, it has been 
demonstrated that biphenyl and fluorinated biphenyl 13, 14 derivatives are metabolised by C. 
elegans in a similar fashion to mammals. Additionally, Rentmeister et al. 15, employed the 
BM3 CYP from Bacillus megaterium to oxidise pharmaceuticals such as ibuprofen, then 
replaced the hydroxyl with fluorine using diethylaminosulfur trifluoride (DAST), resulting in 
fluorinated derivatives with improved membrane permeability.   
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Figure 2.Examples of biphenyl-containing pharmaceuticals 
 
In this paper, we describe proof-of-concept studies concerning a microbial-chemical 
method of identifying the most oxidatively sensitive sites in a range of model biphenyl 
substrates bearing a variety of functional groups by employing C. elegans and the bacterium 
Streptomyces griseus, which is known to also mimic human drug metabolism 16, 17, to 
determine the sites of CYP-catalysed oxidation.  The effect of strategic fluorination on 
metabolism was measured by further incubation of the appropriately fluorinated biphenyl 
system with the microorganisms in an overall strategy to develop systems that are oxidatively 
stable to CYP. This iterative process is shown in Scheme 1 where, ultimiately, a fluorinated 
lead compound with appropriate metabolic stability can be identified in an early stage of the 
drug discovery process. 
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Scheme 1. Chemical-microbial oxidation-fluorination process for drug development 
 
 
Results and discussion 
 
Initially, we incubated a series of commercially available model biphenyl compounds with C. 
elegans and S. griseus, and ethyl acetate extracts from the cultures were analysed by GC-MS 
to identify the products formed (Table 1) from these small scale experiments.   
 
Biphenyl-4-carboxylic acids 
Biphenyl-4-carboxylic acid 1a was completely transformed by C. elegans, but remained 
untransformed by S. griseus.  By GC-MS, one product was detected in the C. elegans extract, 
which had the expected mass spectrum of 4’-hydroxy-biphenyl-4-carboxylic acid 2a, and this 
was confirmed by 1H NMR of the purified compound, which showed two diagnostic AX 
resonances centred at 7.53 and 6.86 ppm attributed to the two 1,4-disubstituted aromatic ring 
systems. 
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Table 1.  Products formed upon incubation of substrate with C. elegans and S. griseus 
Substrate Products after 48 h incubation Yield (%) 
C. elegans 
Yield (%) 
S. griseus 
 
1a 
 
2a 
100 - 
 
1b 
No products detected   
 
1c 
 
2c 
100 - 
 
1d 
 
2b 
100 - 
 
1e 
 
2d 
 
1a 
 
2e 
95 
 
 
- 
 
 
- 
- 
 
 
69 
 
 
21 
  
99 100 
8 
 
1f 1b 
 
1g 
 
2f 
 
2g 
22 
 
 
- 
16.5 
 
 
22.5 
 
1h 
 
2h 
 
2i 
91 
 
 
- 
40 
 
 
15 
 
1i 
 
2j 
 
2k 
 
2l 
30 
 
 
 
42 
 
 
- 
25 
 
 
 
2 
 
 
1 
 
1j 
 
2m 
 
29 
 
 
 
30 
 
 
9 
 
 
2n 
 
2p 
 
61 
 
 
- 
 
1 
 
 
22 
 
Consequently, following the strategy outlined in Scheme 1, the corresponding 4’-fluoro-
biphenyl carboxylic acid 1b was synthesised by Suzuki-Miyaura coupling of 4-fluorobenzene 
boronic acid with ethyl 4-bromobenzoate, followed by acid catalysed hydrolysis (Table 1, 
Supporting Information) following usual procedures and incubated with the microorganisms 
(Table 1). 
We observed that the 4’fluoro biphenyl carboxylic acid 1b is not transformed, 
demonstrating, in this case, that fluorine substitution in a position that favoured hydroxylation 
by CYP will block further oxidation thus exemplifying our strategy described in Scheme 1.  
To further examine the effect of fluorine substitution on the oxidation of biphenyl 
carboxylic acid derivatives, incubation of 2’- or 3’-fluoro-biphenyl-4-carboxylic acid 1c and 
1d with C. elegans was carried out and resulted in 100 % conversion to hydroxylated 
products 2b and 2c respectively whose structure could not be identified with certainty (Table 
1), demonstrating that the 4’-position must bear a fluorine atom to prevent oxidative 
transformation.   
The observation that 2’- and 3’-fluoro-biphenyl-4-carboxylic acid 1c and 1d were 
completely transformed prompted experiments to determine if there was any difference in the 
rate of oxidation at the 4’-positions compared with the non-fluorinated biphenyl 1a. 
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Biphenyl-4-carboxylic acid 1a was completely transformed to the hydroxylated 
product after 48 h incubation, whereas approximately 30 % of the 2’- and 3’-fluorobiphenyl 
carboxylic acid 1c and 1d were converted to the corresponding fluoro-hydroxy-biphenyl-4-
carboxylic acids 2b and 2c in the same time frame, indicating that the presence of fluorine on 
the aryl ring slowed the transformation, reflecting the lower oxidation potential of the 
aromatic ring upon fluorine incorporation. Interestingly, GC-MS analysis showed that the 
composition of the product mixture changed over the course of the experiment; biphenyl-4-
carboxylic acid 1a giving 4-biphenylmethanol, which was detected after 24 h, but was not 
present in the product mixture 48 h incubation (Figure 3).  
Correspondingly, in both the fluorobiphenyl-4-carboxylic acid cultures 1c and 1d, 
fluorinated biphenyl methanol and/or fluorinated hydroxylated biphenyl methanol were 
detected in the extracts, after 24 h and 48 h incubation, but were not present after 72 h, 
leaving the final hydroxylated carboxylic acid (Table 3).  
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Table 3.  Proportion of products formed upon incubation of fluorinated biphenyl-4-carboxylic 
acid with C. elegans for 48 h, as determined by GC-MS.  
 
Fluorine position 
% Product 
Biphenyl methanol OH-biphenyl methanol OH-Carboxylic acid 
Incubation (h) Incubation (h) Incubation (h) 
24 48 24 48 24           48                        
1d, 2’ 3a, 80 3a, 53 4a, 4 4a, 3 -               2b, 29 
1c, 3’ - - a 4b, 65 4b, 63 2c, 30      2c, 34 
1b, 4’ 3c, 69 3c, 93 4c, 2 4c, 3 -        - 
- 2e, 39 - - - 2d, 16     2d, 100 
a 3’-fluorobiphenylmethanol could only be detected after silylation 
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Figure 3.  Gas chromatograms showing the appearance of 4-biphenylmethanol (retention 
time, 9 min) after 24 h incubation of biphenyl-4-carboxylic acid (retention time, 9.3 min) 
with C. elegans (A), and its subsequent disappearance after 48 h with the formation of 4’-
hydroxy-biphenyl-4-carboxylic acid (retention time 12.8 min) (B).  Panel C shows the 
chromatogram from an uninoculated control flask. 
 
 
A 
B 
C 
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Thus, the carboxylic acid group is reduced initially by the culture and then re-
oxidised, possibly reflecting the reducing power available in the cell at the various time 
points of the experiment.  It is also possible that the reduction promotes hydroxylation, of 2’- 
and 3’-fluorobiphenyl-4-carboxylic acid on the second ring, as the –CH2OH group is electron 
donating, activating the ring towards oxidation processes. Interestingly, 4’-fluoro-biphenyl-4-
carboxylic acid 2a was almost completely converted to the biphenyl methanol 3a after 48 h, 
before being re-oxidised back to the acid 2a. The mechanisms of these transformations are 
shown in Scheme 2 and two possible pathways, A and B, can be envisaged.  
 
 
Scheme 2.Transformation of 3’-fluoro-biphenyl carboxylic acid 1c in C. elegans. 
 
Whilst transformation of the acid directly to the hydroxylated acid (Path A) cannot be 
ruled out, the observation of the methanol and hydroxyl methanol derivatives within the 
cultures suggest a step-wise process (Path B) where the reduction of the acid group precedes 
hydroxylation. In the case of the 2’-fluoro derivatives, observation of significant (80%) 
quantities of 2-fluoromethanol derivative shows that the hydroxylation of the aromatic ring is 
a slower process than oxidation of the CH2OH group whereas for the 3’-fluoro derivative, the 
methanol system is not observed indicating rapid hydroxylation, reflecting an increased 
electron donating effect of the CH2OH group on the 3’-fluoro system. Consequently, these in 
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vitro studies provide more information regarding possible metabolite intermediates that may 
be generated compared to in vivo studies in which the final metabolite only may be observed 
upon excretion. 
 The study was expanded by synthesising a range of fluorobiphenyl derivatives with 
varying functional groups by Suzuki-Miyaura coupling reactions (Table 2, Supporting 
Information) and incubating these with the microorganisms as described above (Table 1). 
 
4-Methyl biphenyl 1e 
Incubation of 4-methyl biphenyl 1e with C. elegans resulted in almost complete 
transformation to 4’-hydroxybiphenyl-4-carboxylic acid 2a, indicating both oxidation of the 
methyl group and CYP-mediated hydroxylation.  In S. griseus, two products were detected, 
4-biphenyl methanol and biphenyl-4-carboxylic acid 1a, demonstrating that the oxidation of 
the substrate most likely occurs in a stepwise fashion; however, no hydroxylation of the rings 
occurs, which is consistent with our observations described above.  When 4’-fluoro-4-methyl 
biphenyl 1f was incubated with the microorganisms, the transformation stopped at the 
corresponding carboxylic acid 1b with no ring oxidation, again consistent with results 
described above.   
 
4-Methoxybiphenyl 1g 
Incomplete demethylation of 4-methoxybiphenyl 1g to 2f was observed in C. elegans and S. 
griseus; however, in the bacterium, a highly unusual metabolite, 4-hydroxy-4-phenyl 
cyclohexane 2g, was also detected by GC-MS and the structure was identified by comparison 
with data in the NIST MS database.  The mechanism for this unusual transformation is 
suggested in Scheme 4 and is consistent with a related pathway described by Gopishetty et al. 
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18 in which S. griseus transforms naphthalene to 4-hydroxy-1-tetralone, via 1-naphthol 
(Figure 4). 
 
 
Figure 4.  Proposed CYP-catalysed transformation of naphthalene and methoxy biphenyl in S. 
griseus 
 
 Incubation of fluorinated 4-methoxybiphenyl 1h also resulted in demethylation to 2h in both 
microorganisms, and in C. elegans hydroxylated 2’- and 3’-fluoro-4-methoxybiphenyl 
derivatives 2k and 2n were detected, but no hydroxylated product was detected from 
4’fluoro-4-methoxybiphenyl and is consistent with the previous experiments with 4’-fluoro-
substituted biphenyls. Interestingly, in the S. griseus cultures, a metabolite with the expected 
mass spectrum of fluorinated 4-hydroxy-4-phenyl cyclohexane was detected from 2’, 3’ and 
4’-fluoro-4-methoxybiphenyl. 
 
Nitrobiphenyl 
No transformation of nitrobiphenyl was observed, probably as a consequence of the very 
strong electron withdrawing effect of the nitro group which reduces the oxidation potential of 
the biphenyl system. 
 
Conclusions 
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The incorporation of fluorine into drugs can be an important aspect of hit-to-lead 
development as incorporation of fluorine atoms can have dramatic effects on bioactivity, 
stability and lipophilicity.  In this paper our initial efforts to develop a method for selectively 
fluorinating drugs to improve metabolic stability, by first identifying the most likely site of 
oxidation using microbial transformation, then selectively fluorinating that position has been 
presented (Scheme 1).  The effectiveness of this approach is most clearly demonstrated with a 
model system, biphenyl 4-carboxylic acid, which was completely oxidised to 4’-hydroxy-
biphenyl-4-carboxylic acid by C. elegans, yet the corresponding system 4’-fluoro-biphenyl-4-
carboxylic acid remained unoxidised.  Furthermore, the importance of the regioselectivity of 
fluorine incorporation was illustrated by the incubation of 2’- and 3’-fluoro-biphenyl-4-
carboxylic acid with C. elegans, which resulted in the production of hydroxylated 
metabolites.   
The study also revealed the formation of intermediate/transient metabolites arising 
from metabolism of the fluorinated biphenyl-4-carboxylic acids (biphenyl methanol).  Such 
metabolites are also likely to occur in other species, including mammals, in vivo, and given 
the significance of the relatively new ‘Metabolites in Safety Testing’ (MIST) guidelines from 
the US Food and Drug Administration 19, microoganisms can provide a method for relatively 
easy access to biologically active compounds for toxicity testing.  Thus we have developed 
initial insights into a straightforward microbiological-chemical method for determining the 
optimum site for fluorination and for subsequent evaluation of the metabolism.  Employing 
microorganisms, which are relatively easy to handle, will reduce the costs of using either 
animal models, or mammalian cell cultures.  
 
Experimental 
17 
 
 
Synthesis of fluorobiphenyl derivatives - General procedure 
Aryl boronic acid, potassium carbonate and Pd(PPh3)4 were placed in a round bottomed flask 
filled with an argon atmosphere.  A mixture of toluene (30 mL) and water (1 mL), which had 
been degassed via the freeze-thaw method, and haloarene were added to the flask and the 
mixture was heated at reflux temperature overnight.  The reaction mixture was cooled and 
extracted with water (15 mL) and toluene (15 mL) and separated.  The organic extracts were 
combined and washed with water and brine before being dried (MgSO4). The solution was 
filtered and solvents evaporated to give crude fluorobiphenyl product which was purified by 
column chromatography on silica gel or recrystallization. 
Ethyl 4’-fluorobiphenyl-4-carboxylate 
4-Fluorobenzene boronic acid (1.5 g, 10.7 mmol), potassium carbonate (2.67 g, 19.3 mmol), 
Pd(PPh3)4 (0.37 g, 3.22 mmol), ethyl-4-bromobenzoate (1.6 ml, 9.65 mmol), toluene (30 mL) 
and water (1 mL), after column chromatography on silica gel using ethyl acetate:hexane(1:3) 
as elutant, gave ethyl 4’-fluorobiphenyl-4-carboxylate (1.473 g, 62 %) as a white solid;  mp 
64.5-65.5 °C (lit. 20, 63.5 – 64 oC); (Found: C, 73.6; H, 5.4. C15H13FO2 requires: C, 73.8; H, 
5.3%); vmax (cm
-1) 2991, 1713 (C=O), 1282; δH1.40 (3H, t, J7.1, CH3), 4.39 (2H, q, J 7.1, 
CH2),7.54-7.58 (2H, m, ArH),7.58-7.60 (4H, m, ArH),8.08-8.11  (2H, m, ArH); δF -114.72 
(m);δC14.33 (CH3), 60.97 (CH2),115.82 (d, 
2JCF21.5, C-3’), 126.79 (C-3),128.87 (d, 
3JCF 8.1, 
C-2’),130.08 (C-2),136.14 (d, 4JCF 3.3, C-1’),144.43 (C-4),146.23 (C-1), 162.89 (d, 
1JCF 
247.8, C-4’), 166.37 (C=O); m/z (ASAP+) 244 ([M]+, 100%). 
 
4’-Fluorobiphenyl-4-carboxylic Acid 
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A solution of 4’-fluorobiphenyl -4-carboxylic acid ethyl ester (0.71 g, 2.91 mmol) in THF (8 
mL) and MeOH (8 mL) was treated with 2M NaOH (5mL) at room temperature overnight.  
The organic solvent was evaporated leaving the aqueous layer which was acidified by the 
addition of 2M HCl.  The solution was extracted using ethyl acetate and the organic layers 
combined and dried (MgSO4). The solution was filtered and solvent evaporated to give 4’-
fluorobiphenyl-4-carboxylic acid 21 (0.41 g, 66 %) as a white solid; mp 242.2-244.9 °C; 
(Found: C, 71.9; H, 4.4. C13H9FO2 requires: C, 72.2; H, 4.2%); vmax (cm
-1) 2828, 2554, 1678 
(C=O), 1290; δH(DMSO-d6)7.24-7.32 (2H, m, ArH), 7.70-7.77 (4H, m, ArH),7.95-8.02 (2H, 
m, ArH); δF(DMSO-d6) -114.66 (s); δC(DMSO-d6) 116.31 (d, 
2JCF 21.4, C-3’), 127.15 (C-
2),129.46 (d, 3JCF 8.3, C-2’),130.03 (C-3),130.38 (C-4),135.91 (d, 
4JCF3.1, C-1’),143.64 (C-
1),162.75 (d, 1JCF 245.6, C-4’), 167.53 (CO2H); m/z(ASAP
+) 216 ([M]+, 100%). 
 
Culture conditions 
Streptomyces griseus ATCC 13273 was maintained on agar slants containing ISP4 medium. 
The mycelia were inoculated into 250 mL Erlenmeyer flasks containing 30 mL sterile soya 
bean media consisting of soya bean meal (5 g/L), glycerol (20 g/L), yeast extract (5 g/L) and 
K2HPO4 (5 g/L), and the pH was adjusted to 7. Cultures were incubated with rotary agitation 
(200 rpm) at 30 ⁰C for 72 h. Substituted biphenyl (3 mg) solubilised in 30 µL 
dimethylformamide was added to the flask, and incubation was then continued for a further 
72 h. Cultures were sonicated on ice (Sonicator U200S control, IKA Labortechnik) for 1 min 
at 50 % amplitude and the sonicate centrifuged (3200 rpm, 15 min)to remove the cell debris. 
The supernatant was extracted twice with ethyl acetate (30 mL). 
 Cunninghamella elegans was cultivated on sabouraud dextrose agar for 120 h at 27 
°C. Inoculum was prepared by homogenising the mycelium, including the agar in sterile 8 % 
NaCl (100 mL). The homogenate (5 mL) was then used to inoculate 250 mL Erlenmeyer 
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flasks containing 50 mL sabouraud dextrose broth, which were incubated 72 h with rotary 
agitation (150 rpm) at 27 °C.  Substituted biphenyl (5 mg) solubilised in 50 µL 
dimethylforamide was added to the flask and incubation was continued for a further 72 h. 
Cultures were sonicated on ice for 3 min at 100 % amplitude with 30 s intervals every 
minute. Sonicate was then centrifuged to remove the cell debris and the supernatant was 
extracted twice with ethyl acetate (50 mL). 
 
Metabolite analysis 
Organic extracts were dried and the solid redissolved in ethyl acetate (1 ml), and analysed by 
gas chromatography-mass spectrometry (GC-MS).  Samples (1 μl) were injected in the 
splitless mode onto a HP5MS column (30m x 0.25 mm x 0.25 µm) and the oven temperature 
held at 70 °C for 3 min, then raised to 250 °C at 10 °C min-1.  For the identification of some 
metabolites a portion of the extract was dried under a stream of nitrogen and derivatised by 
heating with N-methyl-N-(trimethyl-silyl) trifluoroacetamide (50 µL) at 100 ⁰C for 1 h.  The 
silylated samples were diluted with ethyl acetate (100 µL) and analysed by GC-MS.  Extracts 
from cultures that were incubated with fluorinated biphenyls were also analysed by fluorine-
19 nuclear magnetic resonance spectroscopy on a Varian 400 MHz spectrometer, after drying 
the extract in a stream of nitrogen and redissolving in CDCl3. 
 4’-Hydroxybiphenyl carboxylic acid was further purified from the organic extracts of 
C. elegans culture supernatants by preparative HPLC using a Varian Prostar system equipped 
with a ZORBAX SB-C18 5µm (150 x 9.4mm) column. Organic extract (250 µL) from eight 
flasks of C. elegans incubated with biphenyl-4-carboxylic acid was injected onto the column 
and the compound was eluted with a gradient of methanol/water (10-90% methanol) over 38 
min with a flow rate of 4 mL min-1.GC-MS analysis of the fractions revealed that the fraction 
containing 4’-hydoxybiphenyl-4-carboxylic acid contained an impurity, which was removed 
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by further HPLC purification with a modified elution gradient: methanol/water (50 %) with a 
gradient of methanol/water (10/90 %) over 25 min and then to (90/10 %) for 13 min with a 
flow rate of 4 mL min-1. The purified compound was characterised by 1H NMR (Varian 300 
MHz spectrometer); δH 6.88 (2H, d, J 9 Hz), 7.53 (2H, d, J 9 Hz), 7.65 (2H, d, J 9 Hz), 8.08 
(2H, d, J 9 Hz). 
Products from transformation of non-fluorinated biphenyl derivatives were identified 
based on their mass spectra employing the NIST MS library. Fluorinated derivatives could be 
readily deduced from the change in mass arising from the presence of fluorine (Supplemental 
Information, Table S1). 
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